Last reviewed · How we verify
Spikevax
At a glance
| Generic name | Spikevax |
|---|---|
| Also known as | SARS-CoV-2-mRNA vaccine, SPIKEVAX Bivalent, Spikevax XBB.1.5, Elasomeran, Davesomeran |
| Sponsor | Jules Bordet Institute |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (PHASE4)
- COVID Protection After Transplant-Immunosuppression Reduction (PHASE2)
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial (PHASE3)
- A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
- A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine
- COVID-19 Protection After Transplant Pilot Study (PHASE2)
- A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults (PHASE3)
- Assessing Immune Response of Different COVID-19 Vaccines in Older Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spikevax CI brief — competitive landscape report
- Spikevax updates RSS · CI watch RSS
- Jules Bordet Institute portfolio CI